Format

Send to

Choose Destination
Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):462-7. doi: 10.1016/j.ijrobp.2007.09.056. Epub 2008 Feb 19.

Proton beam therapy for hepatocellular carcinoma adjacent to the porta hepatis.

Author information

1
Department of Radiation Oncology, University of Tsukuba, Tsukuba, Ibaraki, Japan.

Abstract

PURPOSE:

To evaluate the efficacy and safety of proton beam therapy (PBT) for patients with hepatocellular carcinoma (HCC) located adjacent to the porta hepatis.

METHODS AND MATERIALS:

Subjects of the study were 53 patients with HCC located within 2 cm of the main portal vein. All patients had tumor confined to the radiation field with no evidence of metastatic disease. All patients had hepatic function levels of a Child-Pugh score of 10 or less, Eastern Cooperative Oncology Group performance status of 2 or less, and no uncontrolled ascites. Patients underwent PBT of 72.6 GyE in 22 fractions from Sept 2001 to Dec 2004.

RESULTS:

After 3 years, the actuarial survival rate was 45.1% and local control rate was 86.0%. Prognostic factors for survival included Child-Pugh score, number of tumors, and alpha-fetoprotein levels. No late treatment-related toxicity of Grade 2 or higher was observed.

CONCLUSIONS:

The PBT delivering 72.6 GyE in 22 fractions appears to be effective and safe for HCC adjacent to the porta hepatis.

PMID:
18243571
DOI:
10.1016/j.ijrobp.2007.09.056
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center